Anders Jack 4

What Happened
Anders Jack, Chief Financial Officer of Revolution Medicines (RVMD), executed option/derivative conversions and open‑market sales on June 24, 2026. He acquired 40,000 shares via two derivative transactions (20,000 at $18.56 for $371,200 and 20,000 at $0.00) and sold a total of 20,000 shares in multiple open‑market trades for aggregate proceeds of $3,366,604. The sales were executed under a 10b5‑1 trading plan.

Key Details

• Date of transactions: June 24, 2026; Form 4 filed June 26, 2026 (timely).
• Acquisitions (code M — exercise/conversion): 20,000 shares @ $18.56 = $371,200; 20,000 shares @ $0.00 = $0.
• Sales (code S — open market): 4,553 shares @ $167.34 (weighted avg for that lot) = $761,922; 9,496 shares @ $168.20 = $1,597,188; 5,651 shares @ $169.24 = $956,398; 300 shares @ $170.32 = $51,096. Total sales = 20,000 shares for $3,366,604.
• Multiple‑trade price ranges reported: see footnotes — sales executed across price ranges roughly $166.76–$170.60 (weighted averages shown in filing). Reporting person offered to provide trade‑by‑trade details on request.
• Filing notes the trades were made pursuant to a 10b5‑1 plan adopted March 24, 2026 (footnote F1).
• Filing reports holdings include 51,388 restricted stock units (footnote F2). The filing excerpt does not state total shares owned after these transactions.

Context

• Transaction code M indicates exercise or conversion of derivatives (options/other). Here Jack acquired 40,000 shares via conversion/exercise and sold 20,000 shares the same day — effectively realizing proceeds while retaining the remaining 20,000 newly acquired shares.
• The sales were executed under a pre‑arranged 10b5‑1 plan, which is commonly used to automate insider sales and reduce questions about trading on material nonpublic information.
• These filings are factual disclosures of insider activity and do not, by themselves, indicate company valuation or management sentiment.